Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 12,344.00
Ask: 12,346.00
Change: 68.00 (0.55%)
Spread: 2.00 (0.016%)
Open: 12,268.00
High: 12,388.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Astra's Covid-19 Vaccine Authorised In UK

Wed, 30th Dec 2020 07:49

(Alliance News) - London stock prices are set for a marginally higher open on Wednesday, as the post-Brexit trade deal moves toward implementation and the first jabs of the AstraZeneca vaccine are set to begin early in the New Year.

AstraZeneca said its Covid-19 vaccine has been authorised for emergency supply in the UK.

In other early company news, Energean reported an up to USD405 million purchase of the remaining stake in its Israel unit.

IG says futures indicate the FTSE 100 index of large-caps to open 9.65 points, or 0.2%, higher at 6,612.30 on Wednesday. The FTSE 100 closed up 100.54 points, or 1.6%, at 6,602.65 on Tuesday.

Sterling was quoted at USD1.3550 early Wednesday, rallying from USD1.3509 at the London equities close on Tuesday.

UK house prices surged in December to post their fastest growth in six years, according to the house price index from mortgage lender Nationwide on Wednesday.

House prices jumped 7.3% year-on-year in December, accelerating from rises of 6.5% in November and 5.8% in October to achieve the highest annual growth rate since 2014.

Month-on-month, house prices rose 0.8%, a touch slower than the 0.9% growth seen in November.

The average UK house price stood at GBP230,920 in December versus GBP229,721 in November.

House prices ended the year 5.3% above the level prevailing in March, when the pandemic struck the UK.

The euro traded at USD1.2284 early Wednesday, firming from USD1.2246 late Tuesday.

The UK and EU will on Wednesday sign a mammoth trade pact to put the seal on their drawn-out Brexit divorce in the dwindling hours before they part ways definitively at the dawning of 2021.

EU chiefs Ursula von der Leyen and Charles Michel will ink the 1,246-page Trade & Cooperation Agreement at 0830 GMT, officials in Brussels said, days after it was clinched on Christmas Eve following months of hard-fought talks.

The hefty document will then be flown by the Royal Air Force to London for UK Prime Minister Boris Johnson to add his signature, as the UK parliament embarks on a rushed debate to clear the decks before a December 31 deadline.

According to Downing Street, Johnson will tell MPs that the agreement heralds "a new relationship between Britain and the EU as sovereign equals, joined by friendship, commerce, history, interests and values".

The government only released the accompanying UK legislation on Tuesday afternoon – less than 24 hours before the debate is to start in Parliament an hour after the signing in Brussels.

AstraZeneca said its Covid-19 vaccine has been approved for emergency supply in the UK, with the first doses being released on Wednesday so that vaccinations may begin early in the New Year.

The healthcare company said it aims to supply millions of doses in the first quarter as part of an agreement with the UK government to supply up to 100 million doses in total.

The vaccine was authorised by the UK Medicines & Healthcare Products Regulatory Agency, recommending two doses administered with an interval of between four and 12 weeks. Clinical trials showed the vaccine to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose.

Energean said it has agreed with Kerogen Investments, an affiliate of Kerogen Capital, for the acquisition of Kerogen's 30% shareholding in Energean Israel, which would result in Energean owning 100% of Israel unit share capital.

A total consideration of between USD380 million and USD405 million, the gas exploration and production company said.

Energean said the acquisition adds 2P reserves of 29.5 billion cubic metres of gas and 30 million barrels of liquids, representing 219 million barrels of oil equivalent in total, to the company.

Taking a 100% interest in Energean Israel will enable Energean to fully control its capital structure, it said, enhancing its ability to maximise total shareholder returns.

Exploration and development company Indus Gas reported a decline in pretax profit for the six months to the end of September to USD20.9 million from USD26.1 million a year earlier, as adjusted revenue declined to USD23.2 million from USD27.7 million.

The company said its administrative expenses rose to USD586,360 from USD303,970 year-on-year.

"While the pandemic has presented unprecedented operational challenges, the company remains focused on executing our strategy to maximize value for all of our stakeholders," said Chair Peter Cockburn.

In the US on Tuesday, Wall Street ended lower, with the Dow Jones Industrial Average and the S&P 500 both ending down 0.2% and the Nasdaq Composite down 0.4%.

In Asia on Wednesday, the Japanese Nikkei 225 index closed down 0.5%. Against the yen, the dollar was quoted at JPY103.31, slightly down from JPY103.51.

"The US dollar continued to beat a modest retreat overnight, weakening across the board versus G-10 and Asian currencies," noted Halley.

In China, the Shanghai Composite closed up 1.1%, while the Hang Seng index in Hong Kong was up 1.9%. The S&P/ASX 200 in Sydney closed down 0.3%.

"Asia has a pre-New Year's Eve look about it today, as an empty data calendar combined with an ever-present headline risk leaves the region's financial markets content to drift on the currents," said Halley.

Gold was quoted at USD1,880.65 an ounce early Wednesday, slightly lower than USD1,882.29 on Tuesday. Brent oil was trading at USD51.44 a barrel early Wednesday, firm from USD51.16 late Tuesday.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.